MagnetotherapyNCT07435961
Magnetotherapy in Carpal Tunnel Syndrome: Randomized Controlled Study
A study testing Arm 1: Active Magnetotherapy Group in people with Magnetotherapy and Carpal Tunnel Syndrome (CTS), run by Fatih Sultan Mehmet Training and Research Hospital at 1 site in Turkey (Türkiye).
Trial summary
This study is designed to investigate the effectiveness of low-frequency pulsed electromagnetic field therapy in individuals diagnosed with mild-to-moderate carpal tunnel syndrome (CTS). Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Magnetotherapy, Carpal Tunnel Syndrome (CTS), Median Nerve Compression
- What is being tested?
- Arm 1: Active Magnetotherapy Group
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Feb 2026to 1 Nov 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults aged between 18 and 65 years.
- Clinical diagnosis of carpal tunnel syndrome (CTS) based on physical examination findings, including positive Tinel and/or Phalen tests and hypoesthesia in the 3rd to 5th digits.
- Electrophysiologically confirmed mild-to-moderate carpal tunnel syndrome based on electromyography (EMG) findings.
Who cannot join
- Severe carpal tunnel syndrome confirmed electrophysiologically by electromyography (EMG).
- History of previous surgical intervention for carpal tunnel syndrome.
- Presence of other peripheral nerve entrapments (e.g., ulnar nerve entrapment, radial nerve entrapment).
- Electrophysiologically confirmed polyneuropathy or cervical radiculopathy/cervical discopathy.
- Rheumatologic diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus).
- Diabetes mellitus (Type 1 or Type 2).
Show all 17Show fewer
- Pregnancy.
- Presence of electronic implants such as cardiac pacemaker, cochlear implant, or implantable defibrillator.
- Active acute infection.
- History of malignancy.
- Receipt of physical therapy or rehabilitation for the wrist or surrounding area within the past 6 months.
- Corticosteroid injection to the wrist within the past 6 months.
- Hyperthyroidism or adrenal gland hyperfunction.
- Open growth plates (epiphyseal plates not closed).
- Paroxysmal neurological disorders (e.g., epilepsy).
- Myasthenia gravis.
- Regular use of pain medications such as pregabalin, duloxetine, or non-steroidal anti-inflammatory drugs (NSAIDs).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site
Fatih Sultan Mehmet Research and Training Hospital
Istanbul, Istanbul, 34734
Orçun Ünalan, medical doctor, +905337335856, orcununalan@gmail.com
Orçun Ünalan, MD
About this study
Official title: Evaluation of the Effectiveness of Magnetotherapy in Patients With Carpal Tunnel Syndrome: A Placebo-Controlled, Triple-Arm, Randomized, Double-Blind Study
This study is designed to investigate the effectiveness of low-frequency pulsed electromagnetic field therapy in individuals diagnosed with mild-to-moderate carpal tunnel syndrome (CTS). This double-blind, randomized controlled trial will randomly assign participants into three groups:
Group 1: Active magnetotherapy
Read more
Group 2: Placebo magnetotherapy (treatment using an identical device that does not generate a magnetic field)
Group 3: Routine (conservative) treatment group
All participants will receive a standard nighttime wrist splint and a standardized nerve and tendon gliding exercise protocol. Magnetic field applications will be administered five days per week for a total of 15 sessions. Assessments will be conducted at baseline (T0), at the end of treatment (T1 - Week 3), at 1 month (T2), and at 3 months (T3).
The primary outcome measures include the Boston Carpal Tunnel Questionnaire (BCTQ), pain intensity assessed by the Visual Analog Scale (VAS), functional status measured by QuickDASH, median nerve cross-sectional area assessed by ultrasonography, sensory function evaluated using the Semmes-Weinstein monofilament test, grip strength measured by dynamometry, and clinical test results (Tinel and Phalen tests). Secondary outcomes include sleep quality assessed by the Pittsburgh Sleep Quality Index (PSQI) and patient satisfaction.
This study aims to contribute to the scientific evidence regarding the effectiveness of magnetotherapy as a non-invasive treatment option for carpal tunnel syndrome.
Read the detailed description
Carpal tunnel syndrome (CTS) is a common entrapment neuropathy caused by compression of the median nerve within the carpal tunnel at the wrist, resulting in symptoms such as tingling, numbness, pain, and functional impairment in the hand and fingers. According to the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM), the diagnosis is supported electrophysiologically by delayed distal motor or sensory conduction, conduction block, or prolonged response latency of the median nerve. Clinically, CTS presents with paresthesia, pain, numbness, and functional limitations. The condition is more prevalent among middle-aged individuals, particularly office workers, homemakers, and those engaged in repetitive wrist movements. If left untreated, CTS may lead to muscle weakness and a significant decline in quality of life.
Conservative treatment options include nighttime wrist splinting, nerve mobilization exercises, pharmacological therapy, and physical therapy modalities. However, these approaches are generally symptom-oriented and may have limited long-term effectiveness.
Magnetotherapy has emerged as a non-invasive physical therapy modality with minimal side effects. Pulsed electromagnetic field (PEMF) therapy has been reported to reduce pain and improve objective nerve function in refractory CTS cases in both short- and long-term follow-up. Nevertheless, scientific evidence regarding the effectiveness of magnetotherapy in CTS remains limited, and many existing studies lack robust methodological designs such as placebo control, randomization, and blinding. Therefore, this study aims to contribute to the current literature and strengthen clinical decision-making by providing high-quality evidence on the effectiveness of magnetotherapy in CTS.
- Being tested
- Arm 1: Active Magnetotherapy Group, Arm 2: Sham (Placebo) Magnetotherapy Group, Arm 3: Conservative Treatment (Wait-List Control) Group
- Keywords
- median nerve compression, carpal tunnel syndrome(cts), magnetotherapy
- Medical subject headings
- Carpal Tunnel Syndrome, Median Neuropathy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Arm 1: Active Magnetotherapy GroupDevice
Participants assigned to this group will receive active pulsed electromagnetic field (PEMF) therapy administered five days per week for three consecutive weeks, totaling 15 treatment sessions. Each session will last 15-20 minutes. The treatment will be delivered using a clinically approved medical device set at a frequency of 50 Hz and a magnetic field intensity of 2-3 millitesla (mT). The application will be performed in a controlled clinical setting by trained healthcare personnel.
In addition to magnetotherapy, all participants in this group will receive standard conservative treatment, including the use of a neutral-position wrist splint during nighttime and a standardized home-based exercise program consisting of nerve gliding and tendon gliding exercises. Participants will be instructed on proper exercise performance and adherence will be monitored throughout the study period.
Arm 2: Sham (Placebo) Magnetotherapy GroupDevice
Participants in this group will undergo a sham magnetotherapy procedure using the same device, with identical appearance, positioning, session duration, and application protocol as the active treatment group. However, the device will be set to a mode that does not generate a magnetic field. This approach is designed to maintain participant blinding and control for placebo effects.
Similar to the active group, participants will receive standard conservative treatment consisting of nighttime wrist splint use and the same standardized nerve and tendon gliding home exercise program. Exercise instructions and compliance monitoring will be identical to those of the active treatment group.
Arm 3: Conservative Treatment (Wait-List Control) GroupOther
Participants in this group will receive standard conservative management only, including nighttime wrist splinting and the standardized home-based nerve and tendon gliding exercise program. No magnetotherapy device will be applied during the study period.
To ensure ethical considerations, participants in this group will be placed on a wait-list and may be offered magnetotherapy after completion of the follow-up assessments. Compliance with splint use and exercise performance will be monitored similarly to the other groups.
| Study group | Role | What they receive |
|---|---|---|
| Group 1 (Magnetotherapy Group): | Active comparator | Participants will receive pulsed magnetotherapy five days per week for a total of 15 sessions. Treatment parameters will be 50 Hz frequency, 2-3 mT magnetic field intensity, and 15-20 minutes per session. In addition, participants in this group will use a standard nighttime wrist splint and follow a standardized home exercise program consisting of nerve and tendon gliding exercises. Receives: Device: Arm 1: Active Magnetotherapy Group |
| Group 2 (Placebo Magnetotherapy Group) | Sham comparator | Participants will receive treatment using the same device, with identical appearance and session duration; however, the device will not generate a magnetic field (sham mode). Participants in this group will also use a standard nighttime wrist splint and follow the same standardized home exercise program (nerve and tendon gliding exercises). Receives: Device: Arm 2: Sham (Placebo) Magnetotherapy Group |
| Group 3 (Routine/Conservative Treatment Group) | Other | Participants in this group will use a standard nighttime wrist splint and follow the standardized home exercise program (nerve and tendon gliding exercises). These participants will be placed on a wait-list for magnetotherapy. Receives: Other: Arm 3: Conservative Treatment (Wait-List Control) Group |
What is being measured
The primary outcome is the main question the study is designed to answer.
Symptom Severity Assessed by Boston Carpal Tunnel Questionnaire Symptom Severity Scale
The Boston Carpal Tunnel Questionnaire Symptom Severity Scale is an 11-item patient-reported outcome measure assessing the severity and frequency of carpal tunnel syndrome symptoms. Each item is scored from 1 (no symptoms) to 5 (most severe symptoms). The final score is calculated as the mean of all items, ranging from 1 to 5. Higher scores indicate more severe symptoms and worse clinical outcome.
Measured: Baseline (Week 0), Week 3, Month 1, Month 3
Wrist Pain Intensity Assessed by Visual Analog Scale
Pain intensity will be measured using a 10-centimeter Visual Analog Scale. The scale ranges from 0 to 10, where 0 indicates "no pain" and 10 indicates "worst imaginable pain." Higher scores indicate greater pain severity and worse outcome.
Measured: Baseline (Week 0), Week 3, Month 1, Month 3
Upper Extremity Function Assessed by Quick Disabilities of the Arm, Shoulder and Hand Questionnaire
Upper extremity function will be assessed using the Quick Disabilities of the Arm, Shoulder and Hand Questionnaire. This 11-item validated questionnaire is scored on a 5-point Likert scale and transformed to a total score ranging from 0 to 100. A score of 0 represents no disability and 100 represents maximum disability. Higher scores indicate worse functional impairment.
Measured: Baseline (Week 0), Week 3, Month 1, Month 3
Hand Grip Strength Assessed by Jamar Dynamometer
Hand grip strength will be measured using a calibrated Jamar dynamometer and recorded in kilograms (kg). Higher values indicate greater muscle strength and better functional outcome.
Measured: Baseline (Week 0), Week 3, Month 1, Month 3
Sensory Function Assessed by Semmes-Weinstein Monofilament Test
Sensory function will be evaluated using the Semmes-Weinstein Monofilament Test. Calibrated monofilaments of different thicknesses are applied to standardized fingertip locations to determine sensory threshold levels. Monofilament values range from lower to higher force levels. Higher threshold values indicate greater sensory impairment, whereas lower threshold values indicate better sensory function.
Measured: Baseline (Week 0), Week 3, Month 1, Month 3
Median Nerve Cross-Sectional Area Assessed by Ultrasonography
The cross-sectional area of the median nerve will be measured at the carpal tunnel inlet using high-resolution ultrasonography. Values are recorded in square millimeters (mm²). Higher cross-sectional area values indicate greater nerve swelling and worse pathological status.
Measured: Baseline (Week 0), Week 3, Month 1, Month 3
Clinical Signs Assessed by Tinel and Phalen Tests
The presence or absence of positive Tinel and Phalen signs will be recorded. A positive test indicates median nerve irritation. A reduction in the proportion of positive tests indicates clinical improvement.
Measured: Baseline (Week 0), Week 3, Month 1, Month 3
Secondary outcomes (2)
Sleep Quality Assessed by Pittsburgh Sleep Quality Index
Sleep quality will be assessed using the Pittsburgh Sleep Quality Index. The total global score ranges from 0 to 21. Higher scores indicate poorer sleep quality and worse outcome.
Measured: Baseline (Week 0), Week 3, Month 1, Month 3
Patient Satisfaction Assessed by 5-Point Likert Scale
Patient satisfaction will be assessed using a 5-point Likert scale ranging from 1 (very dissatisfied) to 5 (very satisfied). Higher scores indicate greater satisfaction and better perceived treatment outcome.
Measured: Week 3 (End of Treatment)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Feb 2026
- Study start1 Feb 2026 (estimated)
- Primary completion1 Jun 2026 (estimated)
- Study completion1 Nov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MagnetotherapyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Prospective, Randomized, Placebo-Controlled, Double-Blind Study
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fatih Sultan Mehmet Training and Research Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Orçun Ünalan, Fatih Sultan Mehmet Training and Research Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07435961
- Sponsor's protocol ID
- CTS-MGNT
- Status last verified
- Feb 2026
- First submitted
- 17 Feb 2026
- Last updated
- 27 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data (IPD) will not be shared publicly. All collected data will be de-identified and analyzed for scientific publication purposes only.
Study at a glance
From the registry record, last updated by the sponsor on 27 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Effectiveness of Magnetotherapy in Patients With Carpal Tunnel Syndrome: A Placebo-Controlled, Triple-Arm, Randomized, Double-Blind Study
- ClinicalTrials.gov ID
- NCT07435961
- Acronym / sponsor ID
- CTS-MGNT
- Keywords
- median nerve compression, carpal tunnel syndrome(cts), magnetotherapy
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Fatih Sultan Mehmet Training and Research HospitalUniversity, hospital or other
- Study start
- 1 Feb 2026 (estimated)
- Primary completion
- 1 Jun 2026 (estimated)
- Study completion
- 1 Nov 2026 (estimated)
- First posted
- 27 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is designed to investigate the effectiveness of low-frequency pulsed electromagnetic field therapy in individuals diagnosed with mild-to-moderate carpal tunnel syndrome (CTS). This double-blind, randomized controlled trial will randomly assign participants into three groups:
Group 1: Active magnetotherapy
Group 2: Placebo magnetotherapy (treatment using an identical device that does not generate a magnetic field)
Group 3: Routine (conservative) treatment group
All participants will receive a standard nighttime wrist splint and a standardized nerve and tendon gliding exercise protocol. Magnetic field applications will be administered five days per week for a total of 15 sessions. Assessments will be conducted at baseline (T0), at the end of treatment (T1 - Week 3), at 1 month (T2), and at 3 months (T3).
The primary outcome measures include the Boston Carpal Tunnel Questionnaire (BCTQ), pain intensity assessed by the Visual Analog Scale (VAS), functional status measured by QuickDASH, median nerve cross-sectional area assessed by ultrasonography, sensory function evaluated using the Semmes-Weinstein monofilament test, grip strength measured by dynamometry, and clinical test results (Tinel and Phalen tests). Secondary outcomes include sleep quality assessed by the Pittsburgh Sleep Quality Index (PSQI) and patient satisfaction.
This study aims to contribute to the scientific evidence regarding the effectiveness of magnetotherapy as a non-invasive treatment option for carpal tunnel syndrome.
Detailed description
Carpal tunnel syndrome (CTS) is a common entrapment neuropathy caused by compression of the median nerve within the carpal tunnel at the wrist, resulting in symptoms such as tingling, numbness, pain, and functional impairment in the hand and fingers. According to the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM), the diagnosis is supported electrophysiologically by delayed distal motor or sensory conduction, conduction block, or prolonged response latency of the median nerve. Clinically, CTS presents with paresthesia, pain, numbness, and functional limitations. The condition is more prevalent among middle-aged individuals, particularly office workers, homemakers, and those engaged in repetitive wrist movements. If left untreated, CTS may lead to muscle weakness and a significant decline in quality of life.
Conservative treatment options include nighttime wrist splinting, nerve mobilization exercises, pharmacological therapy, and physical therapy modalities. However, these approaches are generally symptom-oriented and may have limited long-term effectiveness.
Magnetotherapy has emerged as a non-invasive physical therapy modality with minimal side effects. Pulsed electromagnetic field (PEMF) therapy has been reported to reduce pain and improve objective nerve function in refractory CTS cases in both short- and long-term follow-up. Nevertheless, scientific evidence regarding the effectiveness of magnetotherapy in CTS remains limited, and many existing studies lack robust methodological designs such as placebo control, randomization, and blinding. Therefore, this study aims to contribute to the current literature and strengthen clinical decision-making by providing high-quality evidence on the effectiveness of magnetotherapy in CTS.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 3
- Model description
- Prospective, Randomized, Placebo-Controlled, Double-Blind Study
| Arm | Type | Receives |
|---|---|---|
| Group 1 (Magnetotherapy Group): | Active comparator | Device: Arm 1: Active Magnetotherapy GroupParticipants will receive pulsed magnetotherapy five days per week for a total of 15 sessions. Treatment parameters will be 50 Hz frequency, 2-3 mT magnetic field intensity, and 15-20 minutes per session. In addition, participants in this group will use a standard nighttime wrist splint and follow a standardized home exercise program consisting of nerve and tendon gliding exercises. |
| Group 2 (Placebo Magnetotherapy Group) | Sham comparator | Device: Arm 2: Sham (Placebo) Magnetotherapy GroupParticipants will receive treatment using the same device, with identical appearance and session duration; however, the device will not generate a magnetic field (sham mode). Participants in this group will also use a standard nighttime wrist splint and follow the same standardized home exercise program (nerve and tendon gliding exercises). |
| Group 3 (Routine/Conservative Treatment Group) | Other | Other: Arm 3: Conservative Treatment (Wait-List Control) GroupParticipants in this group will use a standard nighttime wrist splint and follow the standardized home exercise program (nerve and tendon gliding exercises). These participants will be placed on a wait-list for magnetotherapy. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Adults aged between 18 and 65 years.
- Clinical diagnosis of carpal tunnel syndrome (CTS) based on physical examination findings, including positive Tinel and/or Phalen tests and hypoesthesia in the 3rd to 5th digits.
- Electrophysiologically confirmed mild-to-moderate carpal tunnel syndrome based on electromyography (EMG) findings.
Key exclusion criteria (17 listed)
- Severe carpal tunnel syndrome confirmed electrophysiologically by electromyography (EMG).
- History of previous surgical intervention for carpal tunnel syndrome.
- Presence of other peripheral nerve entrapments (e.g., ulnar nerve entrapment, radial nerve entrapment).
- Electrophysiologically confirmed polyneuropathy or cervical radiculopathy/cervical discopathy.
- Rheumatologic diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Arm 1: Active Magnetotherapy GroupParticipants assigned to this group will receive active pulsed electromagnetic field (PEMF) therapy administered five days per week for three consecutive weeks, totaling 15 treatment sessions. Each session will last 15-20 minutes. The treatment will be delivered using a clinically approved medical device set at a frequency of 50 Hz and a magnetic field intensity of 2-3 millitesla (mT). The application will be performed in a controlled clinical setting by trained healthcare personnel. In addition to magnetotherapy, all participants in this group will receive standard conservative treatment, including the use of a neutral-position wrist splint during nighttime and a standardized home-based exercise program consisting of nerve gliding and tendon gliding exercises. Participants will be instructed on proper exercise performance and adherence will be monitored throughout the study period. | Device | Group 1 (Magnetotherapy Group): |
| Arm 2: Sham (Placebo) Magnetotherapy GroupParticipants in this group will undergo a sham magnetotherapy procedure using the same device, with identical appearance, positioning, session duration, and application protocol as the active treatment group. However, the device will be set to a mode that does not generate a magnetic field. This approach is designed to maintain participant blinding and control for placebo effects. Similar to the active group, participants will receive standard conservative treatment consisting of nighttime wrist splint use and the same standardized nerve and tendon gliding home exercise program. Exercise instructions and compliance monitoring will be identical to those of the active treatment group. | Device | Group 2 (Placebo Magnetotherapy Group) |
| Arm 3: Conservative Treatment (Wait-List Control) GroupParticipants in this group will receive standard conservative management only, including nighttime wrist splinting and the standardized home-based nerve and tendon gliding exercise program. No magnetotherapy device will be applied during the study period. To ensure ethical considerations, participants in this group will be placed on a wait-list and may be offered magnetotherapy after completion of the follow-up assessments. Compliance with splint use and exercise performance will be monitored similarly to the other groups. | Other | Group 3 (Routine/Conservative Treatment Group) |
Primary outcome
Symptom Severity Assessed by Boston Carpal Tunnel Questionnaire Symptom Severity Scale
Time frame: Baseline (Week 0), Week 3, Month 1, Month 3
The Boston Carpal Tunnel Questionnaire Symptom Severity Scale is an 11-item patient-reported outcome measure assessing the severity and frequency of carpal tunnel syndrome symptoms. Each item is scored from 1 (no symptoms) to 5 (most severe symptoms). The final score is calculated as the mean of all items, ranging from 1 to 5. Higher scores indicate more severe symptoms and worse clinical outcome.
Wrist Pain Intensity Assessed by Visual Analog Scale
Time frame: Baseline (Week 0), Week 3, Month 1, Month 3
Pain intensity will be measured using a 10-centimeter Visual Analog Scale. The scale ranges from 0 to 10, where 0 indicates "no pain" and 10 indicates "worst imaginable pain." Higher scores indicate greater pain severity and worse outcome.
Upper Extremity Function Assessed by Quick Disabilities of the Arm, Shoulder and Hand Questionnaire
Time frame: Baseline (Week 0), Week 3, Month 1, Month 3
Upper extremity function will be assessed using the Quick Disabilities of the Arm, Shoulder and Hand Questionnaire. This 11-item validated questionnaire is scored on a 5-point Likert scale and transformed to a total score ranging from 0 to 100. A score of 0 represents no disability and 100 represents maximum disability. Higher scores indicate worse functional impairment.
Hand Grip Strength Assessed by Jamar Dynamometer
Time frame: Baseline (Week 0), Week 3, Month 1, Month 3
Hand grip strength will be measured using a calibrated Jamar dynamometer and recorded in kilograms (kg). Higher values indicate greater muscle strength and better functional outcome.
Sensory Function Assessed by Semmes-Weinstein Monofilament Test
Time frame: Baseline (Week 0), Week 3, Month 1, Month 3
Sensory function will be evaluated using the Semmes-Weinstein Monofilament Test. Calibrated monofilaments of different thicknesses are applied to standardized fingertip locations to determine sensory threshold levels. Monofilament values range from lower to higher force levels. Higher threshold values indicate greater sensory impairment, whereas lower threshold values indicate better sensory function.
Median Nerve Cross-Sectional Area Assessed by Ultrasonography
Time frame: Baseline (Week 0), Week 3, Month 1, Month 3
The cross-sectional area of the median nerve will be measured at the carpal tunnel inlet using high-resolution ultrasonography. Values are recorded in square millimeters (mm²). Higher cross-sectional area values indicate greater nerve swelling and worse pathological status.
Clinical Signs Assessed by Tinel and Phalen Tests
Time frame: Baseline (Week 0), Week 3, Month 1, Month 3
The presence or absence of positive Tinel and Phalen signs will be recorded. A positive test indicates median nerve irritation. A reduction in the proportion of positive tests indicates clinical improvement.
2 secondary outcomes
Sleep Quality Assessed by Pittsburgh Sleep Quality Index
Time frame: Baseline (Week 0), Week 3, Month 1, Month 3
Patient Satisfaction Assessed by 5-Point Likert Scale
Time frame: Week 3 (End of Treatment)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Feb 2026.
- Individual participant dataSharing planned: No. Individual participant data (IPD) will not be shared publicly. All collected data will be de-identified and analyzed for scientific publication purposes only.
Related trials for Magnetotherapy
Recruiting
Effects of Additional High-Intensity Pulsed Electromagnetic Field (HI-PEMF) Therapy on Pain and Physical Function After Total Hip Replacement
Total Hip Arthroplasty (THA), Magnetotherapy
Recruiting
Molecular Signatures of TMS Response in Treatment-Resistant Depression
Major Depression Disorder
Recruiting
Repetitive Transcranial Magnetic Stimulation Therapy in Spinal Cord Injury Related Neuropathic Pain
Spinal Cord Injuries, Neuropathic Pain
Not yet recruiting
Effect of High-Intensity Focused Electromagnetic Therapy on Balance and Quality of Life in Patients With Multiple Sclerosis
Multiple Sclerosis
Not yet recruiting
High-Intensity Focused Electromagnetic Therapy on Patients With Patellofemoral Pain Syndrome
Patellofemoral Pain Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Arm 1: Active Magnetotherapy Group in people with Magnetotherapy and Carpal Tunnel Syndrome (CTS), run by Fatih Sultan Mehmet Training and Research Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 27 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Orçun Ünalan, medical doctor (+905337335856, orcununalan@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Symptom Severity Assessed by Boston Carpal Tunnel Questionnaire Symptom Severity Scale (time frame: Baseline (Week 0), Week 3, Month 1, Month 3). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Feb 2026.